Beta blockers in systolic heart failure.
Heart failure is a common reason for general practice encounters. It affects 4% of Australians aged 45 years or over with the prevalence increasing from about 1% at age 50-59 years to more than 50% at 84 years of age and over. Patients with heart failure are increasingly managed in the primary care setting, and the emphasis of new national programs on early recognition of signs and diagnosis of heart failure suggest that this trend will continue. Beta blockers have been shown to reduce morbidity and mortality in patients with heart failure when used with an angiotensin converting enzyme inhibitor (ACEI) and a diuretic.
Jackowski
Leslie
L
Sansom Institute, University of South Australia.
Azam
Roshmeen
R
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D015995:Prevalence; D011320:Primary Health Care; D013599:Systole
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D004232:Diuretics